Court grants AstraZeneca temp injunction against Apotex
On 16 April, the US District Court for the District of New Jersey granted Anglo-Swedish drug major AstraZeneca's request for a temporary restraining order, barring Canada-headquartered generic drugmaker Apotex from launching a copy version of AstraZeneca's Pulmicort Respules (budesonide inhalation suspension) until further order of the court. On 27 April, the court will commence a hearing to determine whether the injunction should be continued.
On 30 March, the US Food and Drug Administration granted approval for a generic version of AstraZeneca's product to Apotex. The UK-based firm then filed suit following Apotex' indication of intent to market a generic version of Pulmicort Respules in the USA prior to the expiration of AstraZeneca's patents.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze